Emerging therapies for migraine (Q36992954)

17 August 2017

1 reference

title

Emerging therapies for migraine (English)

1 reference

17 August 2017

1 reference

Peter J Goadsby

1

1 reference

17 August 2017

1 November 2007

1 reference

Nature Clinical Practice Neurology

17 August 2017

1 reference

17 August 2017

3

1 reference

17 August 2017

11

1 reference

17 August 2017

610-619

1 reference

Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts

17 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

Premonitory symptoms in migraine: an electronic diary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

LGI1 gene mutation screening in sporadic partial epilepsy with auditory features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

Migraine--current understanding and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Lost Productive Time and Cost Due to Common Pain Conditions in the US Workforce

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Cost of disorders of the brain in Europe

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Migraine prevalence, disease burden, and the need for preventive therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Unitary hypothesis for multiple triggers of the pain and strain of migraine

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

SUMATRIPTAN: a receptor-targeted treatment for migraine

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Neurogenic inflammation and migraine: implications for the therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Neuroimaging of migraine

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Mechanisms of migraine aura revealed by functional MRI in human visual cortex

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Can we develop neurally acting drugs for the treatment of migraine?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Pathophysiology of the migraine aura. The spreading depression theory

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Suppression of cortical spreading depression in migraine prophylaxis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Migraine, aura, and cortical spreading depression: why are we still talking about it?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Distinct vascular conduction with cortical spreading depression

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

SB-220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

The potential anti-migraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

A double-blind study of SB-220453 (Tonerbasat) in the glyceryltrinitrate (GTN) model of migraine.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

The effect of propranolol on glyceryltrinitrate-induced headache and arterial response

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Botulinum toxin in clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Subcutaneous administration of botulinum toxin A reduces formalin-induced pain

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Treatment of headache with botulinum toxin A--a review according to evidence-based medicine criteria

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

New appendix criteria open for a broader concept of chronic migraine

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Towards a definition of intractable headache for use in clinical practice and trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Re-evaluation of the relationship between migraine and persistent foramen ovale and other right-to-left shunts

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Migraine as a risk factor for subclinical brain lesions

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Vanishing cerebellar infarcts in a migraine patient.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Peripheral neurostimulation for control of intractable occipital neuralgia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Treatment of medically intractable cluster headache by occipital nerve stimulation: long-term follow-up of eight patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Occipital nerve stimulation for drug-resistant chronic cluster headache: a prospective pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Repression of the calcitonin gene-related peptide promoter by 5-HT1 receptor activation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Pharmacological treatment of the ion transport defect in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

The tentorial nerves and Iocalization of intracranial pain in man

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT(1B/1D) receptor agonist activity?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

VR1-immunoreactive primary sensory neurons in the rat trigeminal ganglion.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Capsaicin receptor immunoreactivity in the human trigeminal ganglion.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat--intravital microscope studies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Differential effects of 5-HT1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Nitric oxide in primary headaches

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

The nitric oxide hypothesis of migraine and other vascular headaches

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Glyceryl trinitrate triggers premonitory symptoms in migraineurs

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Migraine can be induced by sildenafil without changes in middle cerebral artery diameter

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Delayed inflammation in rat meninges: implications for migraine pathophysiology.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic pain

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Animal models of migraine: looking at the component parts of a complex disorder.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Nitric oxide synthase inhibition in migraine

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

A group sequential adaptive treatment assignment design for proof of concept and dose selection in headache trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

The pharmacology of headache

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brainstem and spinal cord

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

[3H]Sumatriptan binding sites in human brain: regional-dependent labelling of 5-HT1D and 5-HT1F receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

[3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Autoradiographic localization of 5-HT1E and 5-HT1F binding sites in rat brain: effect of serotonergic lesioning.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0639

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0639

1 reference

17 August 2017

1 reference

PubMed ID

17982431